ICCM News
HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates
HeartFlow (HTFL) delivered earnings and revenue surprises of +70.00% and +11.92%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates
HeartFlow (HTFL) delivered earnings and revenue surprises of +70.00% and +11.92%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026PR NewswireCAESAREA, Israel, Nov. 11, 2026 CAESAREA, Israel, Nov. 11, 2026 /PRNewswire/ -- IceCure...
PR Newswire
IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP PortfolioPR NewswireCAESAREA, Israel, November 9, 2026 Newly Granted Patent Adds to IceCure's...
PR Newswire
Natera (NTRA) delivered earnings and revenue surprises of -129.41% and +13.04%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer CryoablationPR NewswireCAESAREA, Israel, Oct. 27, 2026 First...
PR Newswire
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. SitesPR NewswireCAESAREA, Israel, Oct. 20, 2026 CAESAREA, Israel, Oct. 20...
PR Newswire
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026 IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026PR NewswireCAESAREA, Israel, October 13, 2026Scientific...
PR Newswire
IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical SitePR NewswireCAESAREA, Israel, Oct. 6, 2026CAESAREA...
PR Newswire
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
Zacks
IceCure Medical Receives Regulatory Approval to Market ProSense in China IceCure Medical Receives Regulatory Approval to Market ProSense in China PR Newswire CAESAREA, Israel, Sept. 10, 2026 CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ --IceCure Medical Ltd.(NASDAQ: ICCM) ("IceCure," "IceCure...
PR Newswire